206. 脆弱Ｘ症候群 Disease details / Clinical trials / Drug dev / DR info

11C-flumazenil
   University Antwerp
      2008   -   EUCTR2008-003287-18-BE   Belgium
18F-FTC-146
   Guido A. Davidzon, MD, SM
      2021   Phase 1   NCT04314856   United States
5-hydroxytryptophan / vitamin B6
   Elizabeth Berry-Kravis
      2021   Phase 2   NCT05030129   United States
Acamprosate
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States
      2013   Phase 1   NCT01911455   United States
   Indiana University
      2010   Phase 2   NCT01300923   United States
Acidum ascorbicum D6
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain
AF056
   Novartis
      2008   Phase 2   NCT00718341   France;Italy;Switzerland
AFQ056
   Elizabeth Berry-Kravis
      2017   Phase 2   NCT02920892   United States
   NOVARTIS FARMA
      2012   -   EUCTR2011-002379-40-IT   Australia;Belgium;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2011   -   EUCTR2011-001952-12-IT   Australia;Canada;Denmark;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-022638-96-IT   Australia;Denmark;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2010   -   EUCTR2009-013667-19-IT   Denmark;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-005088-82-IT   France;Italy
   Novartis Farmacéutica S.A
      2012   -   EUCTR2011-002379-40-ES   Australia;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2011-001952-12-ES   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   Phase 2   EUCTR2010-022638-96-ES   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2011   -   EUCTR2009-013667-19-ES   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2012   Phase 1   EUCTR2011-004867-65-ES   Spain;United States
   Novartis Pharma Services AG
      2013   -   EUCTR2011-002379-40-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2011-002379-40-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2010-022638-96-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2010-022638-96-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   -   EUCTR2011-002379-40-SE   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2011-002379-40-GB   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2011-002379-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2011-002379-40-DK   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2012   -   EUCTR2011-002379-40-DE   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 2   EUCTR2011-001952-12-FR   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   Phase 2   EUCTR2011-001952-12-GB   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2011-001952-12-DK   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2011-001952-12-DE   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-022638-96-SE   Australia;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2011   Phase 2   EUCTR2010-022638-96-GB   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-022638-96-DK   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013667-19-GB   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2009-013667-19-DK   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2009-013667-19-DE   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2008   -   EUCTR2007-005088-82-FR   France;Italy
      -   -   EUCTR2011-004867-65-Outside-EU/EEA   Spain;United States
      -   -   EUCTR2011-002379-40-Outside-EU/EEA   Australia;Switzerland;United States
      -   -   EUCTR2010-022638-96-Outside-EU/EEA   Australia;United States
      -   Phase 2   EUCTR2010-022638-96-FR   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   -   EUCTR2010-022638-96-DE   Australia;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      -   -   EUCTR2010-019353-18-Outside-EU/EEA   Switzerland
   Novartis Pharmaceuticals
      2012   Phase 1   NCT01482143   Spain;Switzerland;United States
      2011   Phase 2/Phase 3   NCT01433354   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   NCT01357239   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   NCT01348087   Australia;Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2010   Phase 2   NCT01253629   Australia;Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
Alpha-tocopherol
   Yolanda de Diego Otero
      2010   Phase 2   NCT01329770   Spain
Arbaclofen
   Seaside Therapeutics, Inc.
      2011   Phase 3   NCT01555333   United States
      2011   Phase 3   NCT01325220   United States
      2011   Phase 3   NCT01282268   United States
      2009   Phase 2   NCT01013480   United States
Aripiprazole
   Indiana University School of Medicine
      2007   Phase 2   NCT00420459   United States
Ascorbic acid
   Yolanda de Diego Otero
      2010   Phase 2   NCT01329770   Spain
AZD7325
   Children's Hospital Medical Center, Cincinnati
      2018   Phase 1   NCT03140813   United States
Baclofen
   Children's Hospital Medical Center, Cincinnati
      2022   Phase 2   NCT05418049   United States
      2016   Early Phase 1   NCT02998151   United States
Biological samples
   University Hospital, Tours
      2016   Phase 1   NCT02719951   France
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06147414   France
BPN14770
   Tetra Discovery Partners
      2018   Phase 2   NCT03569631   United States
BPN14770/ zatolmilast
   Tetra Discovery Partners
      2022   Phase 3   NCT05358886   United States
Cannabidiol
   Amsterdam UMC
      2025   Phase 3   EUCTR2021-003250-23-NL   Netherlands
   Zynerba Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-002542-33-IE   Australia;Ireland;United Kingdom;United States
CBD oral solution
   Université de Sherbrooke
      2025   Phase 2   NCT06261502   -
      2025   Phase 2   NCT06261450   -
CCD 1042, MD 9150000, mepalon 1042, SPT316
   Antwerp University Hospital
      2014   -   EUCTR2014-000251-89-BE   Belgium;United States
Cognitive training
   Parc de Salut Mar
      2013   Phase 2   NCT01855971   Spain
CTH120
   Connecta Therapeutics, S.L.
      2023   Phase 1   NCT06480968   Spain
CX516
   Cortex Pharmaceuticals
      2002   Phase 2   NCT00054730   United States
Donepezil
   Stanford University
      2009   Phase 2   NCT01120626   United States
      2005   Phase 1   NCT00220584   United States
Egcg
   Parc de Salut Mar
      2013   Phase 2   NCT01855971   Spain
Egcg fontup
   Parc de Salut Mar
      2018   -   NCT03624556   Spain
Ergoloid mesylate
   Elizabeth Berry-Kravis
      2021   Phase 2   NCT05030129   United States
Flumazenil
   Stanford University
      2016   Phase 1   NCT04308954   United States
Gaboxadol
   Craig Erickson
      2024   Phase 2   NCT06334419   United States
   Healx Limited
      2022   Phase 2   NCT04823052   Australia;United States
   Ovid Therapeutics Inc.
      2018   Phase 2   NCT03697161   United States
Ganaxolone
   Antwerp University Hospital
      2014   -   EUCTR2014-000251-89-BE   Belgium;United States
   Marinus Pharmaceuticals
      2012   Phase 2   NCT01725152   Belgium;United States
Language intervention
   Elizabeth Berry-Kravis
      2017   Phase 2   NCT02920892   United States
Lovastatin
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States
   University of California, Davis
      2016   Phase 4   NCT02642653   United States
Lovastatin, then minocycline/lovastatin
   Université de Sherbrooke
      2016   Phase 2   NCT02680379   Canada
Mavoglurant
   Novartis Pharma Services AG
      2013   -   EUCTR2011-002379-40-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2011-002379-40-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   -   EUCTR2010-022638-96-NL   Australia;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2010-022638-96-BE   Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Indonesia;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      -   -   EUCTR2010-022638-96-Outside-EU/EEA   Australia;United States
      -   -   EUCTR2010-019353-18-Outside-EU/EEA   Switzerland
Memantine
   Children's Hospital Medical Center, Cincinnati
      2022   Phase 2   NCT05418049   United States
Metformin
   Children's Hospital of Fudan University
      2021   Phase 4   NCT05120505   China
   Rowan University
      2019   Phase 1/Phase 2   NCT04141163   United States
   University of Alberta
      2019   Phase 2   NCT03862950   Canada
   University of California, Davis
      2018   Phase 2/Phase 3   NCT03479476   Canada;United States
   Université de Sherbrooke
      2018   Phase 2   NCT03722290   Canada
Methylphenidate oral solution
   University of California, Davis
      2023   Phase 1   NCT05301361   United States
Methylphenidate, fluoxetin, risperidone
   The Chaim Sheba Medical Center
      2001   Phase 4   NCT00768820   Israel
MG01CI extended-release tablet
   Alcobra Ltd.
      2014   Phase 2   NCT02126995   Israel;United States
MGLU5 antagonist
   F. Hoffmann-La Roche Ltd.
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
Minocycline
   Children's Hospital Medical Center, Cincinnati
      2016   Early Phase 1   NCT02998151   United States
   FRAXA Research Foundation
      2007   -   NCT00858689   Canada
Minocycline hydrochloride
   University of California, Davis
      2010   -   NCT01053156   United States
Minocycline, then minocycline/lovastatin
   Université de Sherbrooke
      2016   Phase 2   NCT02680379   Canada
NNZ-2566
   Neuren Pharmaceuticals Limited
      2014   Phase 2   NCT01894958   United States
NON invasive prenatal diagnosis
   University Hospital, Montpellier
      2020   -   NCT04698551   France
NPL-2009
   Neuropharm
      2008   Phase 1/Phase 2   NCT00637221   United States
OV101
   Ovid Therapeutics Inc.
      2018   Phase 2   NCT03697161   United States
      2017   Phase 1   NCT03109756   United States
Oxytocin 24IU
   Stanford University
      2007   Phase 2   NCT01254045   United States
Oxytocin 48IU
   Stanford University
      2007   Phase 2   NCT01254045   United States
Probiotics
   Specila hospital for cerebral palsy and developmental neurology
      2024   -   NCT06279858   Serbia
Psilocybin, 1.5 MG
   Nova Mentis Life Science Corp
      2023   Phase 2   NCT05832255   Canada
Riluzole
   Indiana University
      2009   Phase 4   NCT00895752   United States
RO 491-7523/F18
   F. Hoffmann-La Roche Ltd.
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
RO 491-7523/F19
   F. Hoffmann-La Roche Ltd.
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
RO4917523
   F. Hoffmann-La Roche Ltd.
      2012   -   EUCTR2011-004349-42-SE   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   Phase 2   EUCTR2011-004349-42-GB   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2011-004349-42-ES   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
   Hoffmann-La Roche
      2013   Phase 2   NCT01750957   United States
      2009   Phase 2   NCT01015430   United States
RO4917523 0.5 MG
   Hoffmann-La Roche
      2012   Phase 2   NCT01517698   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
RO4917523 1.5 MG
   Hoffmann-La Roche
      2012   Phase 2   NCT01517698   Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom;United States
Roflumilast
   Children's Hospital Medical Center, Cincinnati
      2022   Phase 2   NCT05418049   United States
Sertraline
   Anagnostou, Evdokia, M.D.
      2024   Phase 2   NCT06081348   Canada
   Randi J. Hagerman, MD
      2012   Phase 2   NCT01474746   United States
SPG601
   Spinogenix
      2024   Phase 2   NCT06413537   United States
STX107
   Seaside Therapeutics, Inc.
      2011   Phase 2   NCT01325740   United States
      2009   Phase 1   NCT00965432   United States
STX209
   Seaside Therapeutics, Inc.
      2009   -   NCT00892580   United States
      2009   -   NCT00823368   United States
      2008   Phase 2   NCT00788073   United States
Sugar pill
   Stanford University
      2009   Phase 2   NCT01120626   United States
Sulindac (HLX-0201), dose strength 1
   Healx Limited
      2022   Phase 2   NCT04823052   Australia;United States
Sulindac (HLX-0201), dose strength 2
   Healx Limited
      2022   Phase 2   NCT04823052   Australia;United States
Tocopheryl acetate
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain
Vitamin C
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain
   Yolanda de Diego Otero
      2010   Phase 2   NCT01329770   Spain
Vitamin E
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2016   Phase 3   EUCTR2015-005460-42-ES   Spain
   Yolanda de Diego Otero
      2010   Phase 2   NCT01329770   Spain
Water
   National Institute of Mental Health (NIMH)
      2006   -   NCT00362843   United States
Zatolmilast
   Tetra Discovery Partners
      2022   Phase 2/Phase 3   NCT05163808   United States
Zatolmilast/ BPN14770
   Tetra Discovery Partners
      2022   Phase 3   NCT05367960   United States
ZYN002
   Zynerba Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-002542-33-IE   Australia;Ireland;United Kingdom;United States
ZYN002 - cannabidiol transdermal GEL
   Zynerba Pharmaceuticals, Inc.
      2018   Phase 2/Phase 3   NCT03802799   Australia;New Zealand;United Kingdom;United States
ZYN002 - CBD transdermal GEL
   Zynerba Pharmaceuticals, Inc.
      2018   Phase 2/Phase 3   NCT03614663   Australia;New Zealand;United States
ZYN002 - transdermal GEL
   Zynerba Pharmaceuticals, Inc.
      2021   Phase 3   NCT04977986   Australia;Ireland;New Zealand;United Kingdom;United States